Which peptides are studied in relation to resolution of inflammation?

Which peptides are studied in relation to resolution of inflammation?

Peptides and proteins studied in the context of inflammation resolution include follistatin (FST), specialized pro-resolving mediators (SPMs), doxycycline (a tetracycline antibiotic with host-directed properties), and recombinant Klotho. Follistatin is a secreted glycoprotein that binds and neutralizes members of the transforming growth factor-beta (TGF-β) superfamily, thereby regulating skeletal muscle, adipose, and bone homeostasis [1]. SPMs are lipid mediators derived from omega-3 fatty acids; a clinical trial is investigating oral SPM supplementation in obese hypertensive patients [2]. Doxycycline is a broad-spectrum antibiotic that also inhibits matrix metalloproteinases (MMPs); clinical trials are testing it as adjunctive host-directed therapy in tuberculosis [3][4]. Klotho is an antiaging protein with anti-inflammatory, antiapoptotic, and antioxidative properties [6].

The work centres on pathways involving TGF-β superfamily signalling, MMP activity, and endogenous resolution mechanisms. Follistatin's effects on adipose browning and lipid metabolism are linked to reduced atherosclerosis in mice [1]. Doxycycline's inhibition of MMPs is being explored to mitigate tissue destruction in central nervous system tuberculosis (CNS-TB) and pulmonary TB [3][4]. SPMs are studied for their potential to resolve vascular inflammation in obese hypertensive patients [2]. Klotho is investigated for mitigating sterile inflammation after hemorrhagic shock [6].

Research Studies

Follistatin and atherosclerosis in mice

In the Hybrid Mouse Diversity Panel (HMDP), transcriptomic and metabolomic analyses revealed that Fst expression was negatively correlated with aortic lesion area [1]. Follistatin promotes adipose browning and enhances energy metabolism, leading to improved plasma lipid profiles and metabolic health in mice [1]. Given the association between brown adipose tissue (BAT) activation and reduced atherosclerosis, investigators studied the anti-atherogenic potential of FST in mice [1].

Specialized pro-resolving mediators and vascular ageing in obese hypertensive patients

A clinical trial (NCT07038252) is investigating the effect of oral SPM supplementation on inflammation-induced vascular ageing in obese hypertensive patients [2]. Cardiovascular risk factors such as obesity, diabetes, high blood pressure, high cholesterol, or smoking are associated with increased risk of myocardial infarction, stroke, or peripheral artery disease [2]. Even with optimal treatment, high-risk individuals face residual cardiovascular risk attributed to vascular lesions largely due to inflammation [2].

Doxycycline and central nervous system tuberculosis

In CNS-TB, the activity of pathogenic host matrix metalloproteinases (MMPs) is unopposed to tissue inhibitors of metalloproteinases (TIMPs), resulting in a matrix-degrading phenotype that may drive worse outcomes [3]. A clinical trial (NCT06446245) is testing adjunctive doxycycline for CNS-TB, based on prior murine model evidence that adjunctive MMP inhibition using doxycycline may improve outcomes [3].

Doxycycline and pulmonary tuberculosis

A Phase 2b double-blind randomised-controlled clinical trial showed that adjunctive doxycycline therapy is safe, accelerates resolution of inflammation, suppresses tissue-damaging enzyme activity, and decreases pulmonary cavity volume [4]. A Phase III trial (NCT05473520) aims to determine if adjunctive doxycycline can reduce pulmonary impairment after tuberculosis (PIAT) and improve cardiovascular outcomes in patients with pulmonary TB [4].

Recombinant Klotho and sterile inflammation after hemorrhagic shock

Hemorrhagic shock induces inflammatory responses, oxidative stress, and apoptosis, often leading to multiple organ failure [6]. Recombinant Klotho protein has been studied for its ability to protect tissues by mitigating the detrimental effects of sterile inflammation after hemorrhagic shock [6].

Dental pulp stem cells and plaque biofilm-associated infections

A structured narrative review synthesised evidence (2000–2025) on the antimicrobial, immunomodulatory, and regenerative properties of dental pulp stem cells (DPSCs) in the context of plaque-induced gingivitis and oral biofilm infections [5].

Comparison of studied compounds

If you are reading this for personal health reasons

The compounds described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Follistatin Mitigates Atherosclerosis Through Activation of Arginine Metabolism and Adipose Browning
• [2] The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients
• [3] Adjunctive Doxycycline for Central Nervous System Tuberculosis
• [4] Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
• [5] Dental Pulp Stem Cells for the Management of Plaque Biofilm-Associated Infections: A Review
• [6] Recombinant Klotho Protein Protects Tissues by Mitigating the Detrimental Effects of Sterile Inflammation After Hemorrhagic Shock